MIM
ATNM icon

Macroview Investment Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Macroview Investment Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-17
Closed -$1K – 146
2017
Q2 		$1K Buy
+17
New +$711 0.01% 174

Other funds holding ATNM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Macroview Investment Management's ATNM Position: Q3 2017 in Review

Macroview Investment Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2017, closing a stake of 17 shares — an estimated $1K sold.

Macroview Investment Management first reported a position in ATNM in Q2 2017 and held it in 1 quarter. The position peaked at $1K in Q2 2017. 31 funds tracked by Wall St. Rank hold ATNM as of Q3 2017.

  • Macroview Investment Management reported no remaining Actinium Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Macroview Investment Management sold 17 Actinium Pharmaceuticals shares in Q3 2017, an estimated $1K.
  • Macroview Investment Management first reported a position in Actinium Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Macroview Investment Management's Actinium Pharmaceuticals position peaked at $1K in Q2 2017.
  • 31 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2017.

Based on Macroview Investment Management's 13F filing for Q3 2017, filed 30 Oct 2017.